Contact Us
Drug Search Results
More Filters [+]

Seletalisib

Alternative Names: seletalisib, usb 5857, ucb-5857, ucb5857
Latest Update: 2023-02-20
Latest Update Note: PubMed Publication

Product Description

Seletalisib is a novel small-molecule inhibitor of PI3K? that was evaluated in biochemical assays, cellular assays of adaptive and innate immunity, and an in vivo rat model of inflammation.

Mechanisms of Action: PI3K Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: UCB
Company Location: SMYRNA GA 30080
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Seletalisib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Sjogren's Syndrome

Phase 1: Healthy Volunteers|Psoriasis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2015-005541-30

P3

Completed

Unknown

2018-12-13

2015-002900-10

P1

Completed

Unknown

2018-01-23

2014-004523-51

P2

Terminated

Sjogren's Syndrome

2017-09-27

SS0004

P2

Terminated

Sjogren's Syndrome

2017-09-07

24%

Recent News Events

Date

Type

Title

02/20/2023

PubMed

 Molecular Insight into Drug Resistance Mechanism Conferred by Aberrant PIK3CD Splice Variant in African American Prostate Cancer.

09/01/2022

PubMed

 The phosphoinositide-3-kinase (PI3K)-delta inhibitor seletalisib impairs monocyte-derived dendritic cells maturation, APC function, and promotes their migration to CCR7 and CXCR4 ligands.

10/02/2021

PubMed

 PI3Kδ Sustains Keratinocyte Hyperproliferation and Epithelial Inflammation: Implications for a Topically Druggable Target in Psoriasis.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions